Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers
(d) Election of New Directors.
On August 23, 2021, the board of directors (the "Board") of Applied Molecular
Transport Inc. (the "Company") increased the size of the board from six members
to seven members and appointed Holly Schachner to serve as a Class III director
on the Board for a term expiring at the 2023 annual meeting of the Company's
stockholders. Dr. Schachner was appointed to the Corporate Governance and
Nominating Committee and Compensation Committee of the Board, effective
immediately.
Dr. Schachner will receive standard compensation, including cash compensation
and option grants available to non-employee directors pursuant to the Company's
director compensation policy. In addition, Dr. Schachner has entered into the
Company's standard indemnification agreement.
There are no arrangements or understandings between Dr. Schachner and any other
persons pursuant to their respective appointments, no family relationships
between Dr. Schachner and any director or executive officer of the Company, and
Dr. Schachner does not have a direct or indirect material interest in any
related party transaction required to be disclosed pursuant to Item 404(a) of
Regulation S-K.
Attached to this Form 8-K is a press release regarding the appointment of
Dr. Schachner as a director of the Company. The information in the press release
attached hereto shall not be deemed "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act of
1934, as amended.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release, dated August 24, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Applied Molecular Transport Inc.
By: /s/ Tahir Mahmood
Tahir Mahmood, Ph.D.
Co-Founder and Chief Executive Officer
Date: August 24, 2021
© Edgar Online, source Glimpses
APPLIED MOLECULAR TRANSPORT INC. 
